Bionano Genomics Inc
$ 1.70
-1.73%
04 Dec - close price
- Market Cap 16,456,500 USD
- Current Price $ 1.70
- High / Low $ 1.77 / 1.69
- Stock P/E N/A
- Book Value 5.12
- EPS -12.77
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.78 %
- 52 Week High 22.80
- 52 Week Low 1.45
About
Bionano Genomics, Inc. (BNGO) is a cutting-edge life sciences company based in San Diego, California, that specializes in advanced genome analysis solutions. Utilizing its proprietary Saphyr system, Bionano enhances the understanding of genomic variations linked to diseases, particularly in cancer research, genetic disorders, and prenatal testing. The company's innovative technology places it at the forefront of the genomics industry, driving advancements in personalized medicine and improving patient outcomes. With a strong commitment to innovation and a rapidly growing market, Bionano Genomics is well-positioned for significant growth and impact in the field of genetic analysis.
Analyst Target Price
$7.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-14 | 2025-06-18 | 2025-03-03 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-03-05 | 2023-11-08 | 2023-08-09 | 2023-05-09 | 2023-03-09 |
| Reported EPS | -1.59 | -1.99 | -10.7888 | -7.73 | -0.2675 | -0.22 | -0.51 | -0.9593 | -1 | -1.24 | -0.12 | -0.13 |
| Estimated EPS | -2.34 | -0.54 | -3.0233 | -6 | -0.21 | -0.42 | -0.64 | -0.87 | -0.97 | -1.03 | -0.11 | -0.11 |
| Surprise | 0.75 | -1.45 | -7.7655 | -1.73 | -0.0575 | 0.2 | 0.13 | -0.0893 | -0.03 | -0.21 | -0.01 | -0.02 |
| Surprise Percentage | 32.0513% | -268.5185% | -256.8551% | -28.8333% | -27.381% | 47.619% | 20.3125% | -10.2644% | -3.0928% | -20.3883% | -9.0909% | -18.1818% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BNGO
2025-11-02 11:30:30
BioNano Genomics announced the completion of a public offering on September 17, 2025, which raised approximately $9 million in net proceeds. These funds are intended for working capital and general corporate purposes. Despite the capital raise, an AI analyst maintains a "Neutral" stance on the stock due to weak financial performance and valuation challenges, though the company reports some positive insights like improved margins.
2025-10-21 05:04:54
Bionano Genomics (NASDAQ: BNGO) announced the pricing of a $10 million public offering, consisting of 5 million shares of common stock and accompanying Series E and F warrants, priced at $2.00 per share. If all warrants are fully exercised, the company could receive an additional $20 million in gross proceeds. The offering is expected to close around September 17, 2025, with proceeds earmarked for working capital and general corporate purposes.
2025-10-21 05:04:54
Bionano Genomics, Inc. announced that its President and CEO, Erik Holmlin, PhD, will participate in the H.C. Wainwright @ Home Event on October 15, 2025. He will present from 10:00 a.m. to 11:00 a.m. ET, with a webcast available for registration and a replay obtainable on the Bionano website. The company also provided an overview of its genome analysis solutions and contact information for company and investor relations.
2025-10-21 05:04:54
Bionano Genomics, Inc. announced the pricing of a public offering expected to raise approximately $10 million in gross proceeds. The offering includes 5,000,000 shares of common stock (or equivalents) and Series E and F warrants to purchase an additional 10,000,000 shares, priced at $2.00 per share and warrant. The company intends to use the net proceeds for working capital and general corporate purposes.
2025-09-16 13:22:00
Bionano Genomics, Inc. announced the pricing of a public offering of 5 million shares of common stock and Series E and Series F warrants at $2.00 per share, aiming to raise approximately $10 million before expenses. The offering, expected to close around September 17, 2025, could generate an additional $20 million if the warrants are fully exercised. The company plans to use the net proceeds for working capital and general corporate purposes, with H.C. Wainwright & Co. serving as the exclusive placement agent.
2025-09-14 00:00:00
Bionano Genomics, Inc. (NASDAQ:BNGO) experienced a 28% share price gain in the last month, yet this did little to offset an 85% decline over the past year. Despite a low price-to-sales (P/S) ratio of 0.7x, which generally signals undervaluation compared to the Life Sciences industry average of 3.2x, the company's past revenue decline contrasts with its forecasted 29% annual revenue growth for the next three years, exceeding the industry's 7.0%. The article suggests that investor skepticism about the company's future growth expectations may be contributing to the depressed P/S ratio, despite the positive outlook.
